Bazedoxifene, a selective estrogen receptor modulator, has been proven to be an effective GP130/STAT3 signaling inhibitor, inhibiting growth and migration of pancreatic cancer cells in animal studies [9]. This evidence concerns the gene STAT3 and pancreatic neoplasm.